PharmWeb

Ian Stratford

Prof. Ian Stratford


Research

Anti-cancer drug discovery, synthesis and evaluation
Enzyme-directed drug activation for specific tumour therapy
Tumour biology, tumour physiology, anti-antiogenesis and vascular targeting
Gene therapy of cancer: Cell and molecular biology
Manipulation of tumour oxygenation for therapeutic benefit

Career Details

Ian Stratford received his Ph.D. in 1975 in the Department of Pharmacy (University of Manchester). He spent the next 20 years carrying out cancer research at the CRC Gray Laboratory (Mt. Vernon Hospital, London), the Institute of Cancer Research / Royal Marsden Hospital (Sutton) and most recently at the MRC Radiobiology Unit (Oxford), where he was Head of the Division of Experimental Oncology. He joined the Manchester Department of Pharmacy as Professor in January 1996 and brings with him the largest MRC Programme grant currently tenable in a U.K. Pharmacy Department. His team includes experts in synthetic chemistry and molecular, cellular and tumour biology. The primary aim of their work will be to build on their previous success on identifying novel molecular targets based on the abnormal physiology that exists in solid tumours. New anti-cancer drugs will then be developed that can be selectively directed at these targets.

Recent Publications include

BARHAM, H. and STRATFORD, I.J. 1996
Enzymology of the reduction of the novel fused pyrazine mono-N-oxide bioreductive drug, RB90740: Roles for P450 reductase and cytochrome b5 reductase.
Biochem. Pharm. 51, 829-837.

PATTERSON, A., BARHAM, H., CHINJE, E., ADAMS, G.E., HARRIS, A.L. and STRATFORD, I.J. 1995
Importance of P450 reductase activity in breast tumour cells for determining sensitivity to the bioreductive drug, tirapazamine (SR 4233).
Br. J. Cancer 72, 1144-1150.

NAYLOR, M., ADAMS, G.E., HAIGH, A., COLE, S., JENNER, T., ROBERTSON, N., SIEMANN, D., STEPHENS, M.A., and STRATFORD, I.J. 1995.
Fused pyrazine mono-N-oxides as bioreductive drugs III. Characterization of RB 90740 in vitro and in vivo.
Anti Cancer Drugs 6, 259-269.

PATTERSON, A.V., ZHANG, H., MOGHADDAM, A., BICKNELL, R., TALBOT, D.C., STRATFORD, I.J., and HARRIS, A.L., 1995.
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
Br. J. Cancer 72, 669-675.

WOOD, P.J., SANSOM, J.M., BUTLER, S.A., STRATFORD, I.J., COLE, S.M., SZABO, C., THIEMERMANN, C. and ADAMS, G.E. 1994.
Induction of hypoxia in experimental murine tumours by the nitric oxide synthase inhibitor, nitro-L-arginine.
Cancer Res. 54, 6455-6463.

Further Information

Tel: +44 (0)161 275 2869 (lab. -office phone not connected yet)
Fax: +44 (0)161 275 2396
E-mail: IANS@fs1.pa.man.ac.uk


PharmWeb
PharmWeb - Copyright©1994-1998. All rights reserved